- Organic metal compound and organic light-emitting device
-
Organic metal compounds and organic light-emitting devices employing the same are provided. The organic metal compound has a chemical structure of Formula (I) or Formula (II): In particular, one of the following two conditions (1) and (2) is met: (1) R1 is deuterium or C1-6 deuterated alkyl group, when R3 and R4 are independently hydrogen, halogen, C1-6 alkyl group, C1-6 fluoroalkyl or C3-12 heteroaryl group; and (2) R1 is hydrogen, deuterium, C1-6 alkyl group, C1-6 deuterated alkyl group, C3-12 heteroaryl group, or C6-12 aryl group, when at least one of R3 and R4 is C6-12 aryl group or C6-12 fluoroaryl group.
- -
-
-
- One-pot synthesis of fused 2-pyridones from heteroarylacrylic acid via curtius rearrangement & microwave-assisted thermal electrocyclization
-
We investigated the one-pot synthesis of several fused 2-pyridone ring systems based on a Curtius rearrangement, followed by a microwave-assisted thermal electrocyclization of a 2-aza-6?-electron system including isocyanate. We synthesized seven heterocyclic compounds containing a fused 2-pyridone ring. In these results, the one-pot synthesis of fused 2-pyridone ring system 5 from (E)-acrylic acids 1 under microwave irradiation conditions was more effective than the conventional reaction conditions in terms of the yield and the reaction time.
- Nishiyama, Takashi,Hatae, Noriyuki,Hayashi, Kaori,Obata, Manami,Taninaka, Kimiko,Yamane, Masahiro,Oda, Shota,Abe, Takumi,Ishikura, Minoru,Hibino, Satoshi,Choshi, Tominari
-
p. 251 - 267
(2017/07/28)
-
- A novel furo[3,2-: C] pyridine-based iridium complex for high-performance organic light-emitting diodes with over 30% external quantum efficiency
-
A novel furo[3,2-c]pyridine based Ir complex, namely (pfupy)2Ir(acac), has been developed by replacing sulfur with oxygen in the C^N ligand. Compared with the thiophene-containing (pthpy)2Ir(acac), the LUMO level is elevated while the HOMO level remains almost unchanged for the resultant furan-containing (pfupy)2Ir(acac). As a consequence, the emissive maximum is blue-shifted from 556 nm of (pthpy)2Ir(acac) to 538 nm of (pfupy)2Ir(acac) together with an improved photoluminescence quantum yield of 0.80. The corresponding device based on (pfupy)2Ir(acac) realizes a record-high external quantum efficiency (EQE) of 30.5% (110.5 cd A-1) without any out-coupling technology. Even at a luminance of 1000 and 5000 cd m-2, the EQE still remains at 26.6% (96.4 cd A-1) and 25.6% (92.7 cd A-1), respectively, indicative of the gentle efficiency roll-off. The results clearly demonstrate the great potential of furan-based functional materials applied in OLEDs.
- Yan, Zhimin,Wang, Yanping,Wang, Jiaxiu,Wang, Yue,Ding, Junqiao,Wang, Lixiang
-
supporting information
p. 10122 - 10125
(2017/10/19)
-
- NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS
-
This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.
- -
-
-
- IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION
-
The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.
- -
-
-
- Design and synthesis of piperazinylpyridine derivatives as novel 5-HT 1A agonists/5-HT3 antagonists for the treatment of irritable bowel syndrome (IBS)
-
We have prepared a series of piperazinylpyridine derivatives for the treatment of irritable bowel syndrome (IBS). These compounds, which were designed by pharmacophore analysis, bind to both serotonin subtype 1A (5-HT 1A) and subtype 3 (5-HT3) receptors. The nitrogen atom of the isoquinoline, a methoxy group and piper-azine were essential to the pharmacophore for binding to these receptors. We also synthesized furo- and thienopyridine derivatives according to structure-activity relationship analyses. Compound 17c (TZB-20810) had high affinities to these receptors and exhibited 5-HT1A agonistic activity and 5-HT3 antagonistic activity concurrently, and is a promising drug for further development in the treatment of IBS.
- Asagarasu, Akira,Matsui, Teruaki,Hayashi, Hiroyuki,Tamaoki, Satoru,Yamauchi, Yukinao,Sato, Michitaka
-
experimental part
p. 34 - 42
(2009/07/18)
-
- TRICYCLIC COMPOUND AND MEDICAL USE THEREOF
-
The present invention provides a compound represented by the formula wherein R1 is a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or a heterocyclic group optionally having substituent(s), R2 is a hydrogen atom or a hydrocarbon group optionally having substituent(s), R3 is a hydrogen atom, a halogen atom, a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or mercapto optionally having a substituent, Xa to Xe are each a carbon atom or a nitrogen atom, m is 0 to 2, and ring A to ring C are each a ring optionally having substituent(s), or a salt thereof, which is useful as an agent for the prophylaxis or treatment of a disease relating to an action of melatonin, and the like.
- -
-
Page/Page column 44
(2009/09/28)
-
- Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases
-
A novel class of 3,7-diphenyl-4-amino-thieno and furo[3,2-c]pyridine has been designed based on pharmacophore models of ATP competitive kinase inhibitors. Versatile synthetic methods via double Suzuki coupling to explore SAR have been established and potent inhibitors against angiogenetic targets, VEGFR2, Tie-2, and EphB4, have been successfully discovered.
- Miyazaki, Yasushi,Nakano, Masato,Sato, Hideyuki,Truesdale, Anne T.,Stuart, J. Darren,Nartey, Eldridge N.,Hightower, Kendra E.,Kane-Carson, Laurie
-
p. 250 - 254
(2007/10/03)
-
- AZABENZOFURAN SUBSTITUTED THIOUREAS; INHIBITORS OF VIRAL REPLICATION
-
The present invention provides compounds of Formula: (1), wherein the variables Ar, A1, A2, A3, A4, R5, R6, R7, V, W, X, and Y are defined herein. Certain compounds of Formula (1
- -
-
-
- NOVEL CHEMICAL COMPOUNDS
-
This invention relates to newly identified compounds for treating and preventing tumors ans cancers, and methods for treating proliferative diseases associated with the imbalance or inappropriate activity of tyrosine kinases implicated in proliferative diseases.
- -
-
Page 20-21; 16
(2008/06/13)
-
- Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors
-
Replacement of the highly basic benzamidine moiety with moderate basic amino-bicycloaryl moieties in a series of thrombin inhibitors related to NAPAMP provided potent enzyme inhibition and significant improvements in membrane transport and oral bioavailability.
- Rewinkel,Lucas,Smit,Noach,Van Dinther,Rood,Jenneboer,Van Boeckel
-
p. 2837 - 2842
(2007/10/03)
-
- Furopyridines. XIX [1]. Reaction of furo[2,3-b]-, -[3,2-b]-, -[2,3-c]- and -[3,2-c]pyridine with acetic anhydride
-
Acetoxylation of N-oxide of furo[2,3-b]- 2a, -[3,2-b]- 2b, -[2,3-c]- 2c and -[3,2-c]pyridine 2d with acetic anhydride afforded compounds substituted normally at the α- or γ-position to the ring nitrogen, 3a, 4a, 4b, 3d, 4d, 8 and 9, and in addition compounds substituted on the furan ring, 5a, 6a, 5b, 6b, 7b, 5c and 7c which were unexpected compounds. The structures of these compounds were established from the ir, nmr and mass spectra, and x-ray crystal analysis of 5b.
- Shiotani, Shunsaku,Taniguchi, Katsunori,Ishida, Toshimasa,In, Yasuko
-
p. 647 - 654
(2007/10/03)
-
- PSYCHOTROPIC HETEROBICYCLOALKYLPIPERAZINE DERIVATIVES
-
A series of psychotropic heterobicycloalkylpiperazine derivatives having the structure STR1 wherein V is a 3-or 4-membered unsaturated chain, containing all carbon atoms when 4-membered, or when a 3-membered chain, V contains an oxygen or sulfur atom as one of the members; R is H or C 1-4 alkyl; W is CH, N, CH 2, or a chemical bond; X is CH, N, SO 2, or CO, with the proviso that both W and X cannot simultaneously be N; and Z is a heteroaromatic ring system. These compounds are useful antipsychotic and/or anxiolytic agents.
- -
-
-
- The Thienopyridine and Furopyridine Rings: New Pharmacophores with Potential Antipsychotic Activity
-
Two new arylpiperazine derivatives, the 4-(1-piperazinyl)thieno- and -furopyridine ring systems, have been synthesized and appended via tetramethylene chains to various imide rings.Target compounds from each series were found to have significant activity in the blockade of apomorphine stereotypy and apomorphine-induced climbing, the Sidman avoidance response, and the conditioned avoidance response.In addition, while potent affinity for serotonin 5-HT1 and 5-HT2 receptors was observed for both the thieno- and furopyridine derivatives,the interaction of these molecules with the dopamine D2 receptor was weak.Electrophysiological studies of the lead prototypes from each series, involving compounds 22 and 33, indicate these two molecules have distinctively different effects on dopamine neurons in areas A9 and A10.Despite the similarity these molecules share in their behavioral indices of antipsychotic acivity, it is likely that the thieno- and furopyridine rings employ different mechanisms to achieve this convergence of biological effects.
- New, James S.,Christopher, William L.,Yevich, Joseph P.,Butler, Rhett,Schlemmer, R. Francis,et al.
-
p. 1147 - 1156
(2007/10/02)
-
